Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.3)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 6, September, p. 1031–1036

doi: 10.17219/acem/61435

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Relationship between toxoplasmosis and schizophrenia: A review

Aleksander J. Fuglewicz1,A,B,C,D,E,F, Patryk Piotrowski2,A,B,C,D,E,F, Anna Stodolak1,A,B,C,D,E,F

1 Department of Social Pediatrics, Faculty of Health Science, Wroclaw Medical University, Poland

2 Department of Psychiatry, Faculty of Postgraduate Medical Training, Wroclaw Medical University, Poland

Abstract

A growing body of evidence suggests a correlation between schizophrenia and exposure to infectious agents. The majority of studied cases concerns the infection caused by T. gondii, an obligatory intracellular parasite that infects about 1/3 of the entire human population, according to the available data. The acute stage of the disease, predominantly short-lived and transient, transforms into the latent and chronic phase in which the parasite localizes within tissue cysts, mainly in the central nervous system. The chronic toxoplasmosis, primarily regarded as benign and asymptomatic, might be responsible, in light of current scientific evidence, for a vast array of neuropsychiatric symptoms. Numerous epidemiological case-control studies show a higher prevalence of T. gondii infestation in individuals with various psychiatric and behavior disorders, including schizophrenia. This paper tends to review the relevant studies that demonstrate links between schizophrenia and T. gondii infestation, of which the latter may be acquired in different developmental phases. Apart from epidemiological correlation studies, some papers on other associations were also presented, describing putative patophysiological mechanisms that might be at least partly responsible for chronic infection-induced neuromediator disturbances, together with morphological and functional alterations, e.g., low-grade neuroinflammation, which are likely to induce psychopathological symptoms. Toxoplasmosis is only one of the putative infectious agents that derange correct brain growth and differentiation, alongside genetic and environmental factors. All of them may lead eventually to schizophrenia. A better knowledge of infection mechanisms and its influence on neurobiochemical and neuropathological pathways may enable more efficient therapy and the prevention of this devastating disease.

Key words

neuropsychiatric symptoms, schizophrenia, Toxoplasma gondii

References (40)

  1. Flegr J, Prandota J, Sovickova M, Israili ZF. Toxoplasmosis – a global threat: Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS ONE. 2014;9:e90203.
  2. Jones JL, Parise ME, Fiore AE. Neglected parasitic infections in the United States: Toxoplasmosis. Am J Trop Med Hyg. 2014;90:794–799.
  3. McConkey GA, Martin HL, Bristow GC, Webster JP. Toxoplasma gondii infection - location, location, location? J Exp Biol. 2013;216:113–119.
  4. Henriquez SA, Brett R, Alexander J, Pratt J, Roberts CW. Neuropsychiatric disease and Toxoplasma gondii infection. Neuroimmunomodulation. 2009;16:122–133.
  5. Torrey EF, Yolken RH. Toxoplasma gondii and schizophrenia. Emerg Infect Dis. 2003;9:1375–1380.
  6. Torrey EF, Bartko JJ, Lun ZR, Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: A meta-analysis. Schizophr Bull. 2007;33:729–736.
  7. Torrey EF, Bartko JJ, Yolken RH. Toxoplasma gondii and other risk factors for schizophrenia: An update. Schizophr Bull. 2012;38:642–647.
  8. Kozar Z. Badania nad toksoplazmozą wśród umysłowo chorych. Bull Inst Mar Trop Med Gdańsk. 1953;5:146–173.
  9. Carruthers VB, Suzuki Y. Effects of Toxoplasma gondii infection on the brain. Schizophr Bull. 2007;33:745–751.
  10. Ebadi M, Akhlaghi H, Zamani MM, et al. The correlation between Toxoplasma gondii infection and schizophrenia: A comparative study with family members (control group). Scimetr. 2014;2:e15386.
  11. Dickerson F, Boronow J, Stallings C, Origoni A, Yolken R. Toxoplasma gondii in individuals with schizophrenia: Association with clinical and demographic factors and with mortality. Schizophr Bull. 2007;33:737–740.
  12. Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull. 2006;32:200–202.
  13. Brown AS, Patterson PH. Maternal infection and schizophrenia: Implications for prevention. Schizophr Bull. 2011;37:284–290.
  14. Khandaker GM, Zimbron J, Lewis G, Jones PB. Prenatal maternal infection, neurodevelopment and adult schizophrenia: A systematic review of population-based studies. Psychol Med. 2013;43:239–257.
  15. Brown AS, Schaefer CA, Quesenberry CP, Liu L, Babulas VP, Susser ES. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry. 2005;162:767–773.
  16. Mortensen PB, Nørgaard-Pedersen B, Waltoft BL, et al. Toxoplasma gondii as a risk factor for early-onset schizophrenia: Analysis of filter paper blood samples obtained at birth. Biol Psychiatry. 2007;61:688–693.
  17. Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res. 2003;62:237–244.
  18. Webster JP, Lamberton PHL, Donnelly CA, Torrey EF. Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour. Proc R Soc B. 2006;273:1023–1030.
  19. Fond G, MacGregor A, Tamouza R, et al. Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. Eur Arch Psychiatry Clin Neurosci. 2014;264:179–183.
  20. Kar N, Misra B. Toxoplasma seropositivity and depression: A case report. BMC Psychiatry. 2004;4:1.
  21. Webster JF, McConkey GA. Toxoplasma gondii-altered host behaviour: Clues as to mechanisms of action. Folia Parasitol. 2010;57:95–104.
  22. Gaur N, Gautam S, Gaur M, Sharma P, Dadheeh G, Mishra S. The biochemical womb of schizophrenia: A review. Indian J Clin Biochem. 2008;23:307–327.
  23. Eyles D, Feldon J, Meyer U. Schizophrenia: Do all roads lead to dopamine or is this where they start? Evidence from two epidemiologically informed rodent models. Transl Psychiatry. 2012;2:e81.
  24. Campbell BM, Charych E, Lee AW, Moller T. Kynurenines in CNS disease: Regulation by inflammatory cytokines. Front Neurosci. 2014;8:12.
  25. Minto A, Roberts FJ. The psychiatric complications of toxoplasmosis. Lancet. 1959;1:1180–1182.
  26. Dube B, Benton T, Cruess DG, Evans DL. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci. 2005;30:237–246.
  27. Kamerkar S, Davis PH. Toxoplasma on the brain: Understanding host-pathogen interactions in chronic CNS infection. J Parasitol Res. 2012. DOI: 10.1155/2012/589295.
  28. Vyas A, Sapolsky R. Manipulation of host behaviour by Toxoplasma gondii: What is the minimum a proposed proximate mechanism should explain? Folia Parasitol. 2010;57:88–94.
  29. Hurley RA, Taber KH. Latent Toxoplasmosis gondii: Emerging evidence for influences on neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci. 2012;24:376–383.
  30. Lyons RE, McLeod R, Roberts CW. Toxoplasma gondii tachyzoite-bradyzoite interconversion. Trends Prasitol. 2002;18:198–201.
  31. Venkatasubramanian G, Debnath M. Neuroimmunological aberrations and cerebral asymmetry abnormalities in schizophrenia: Select perspectives on pathogenesis. Clin Psychopharmacol Neurosci. 2014;12:8–18.
  32. Muller N. The role of anti-inflammatory treatment in psychiatric disorders. Psychiatria Danubina. 2013;25:292–298.
  33. Hanauer DA, Ramakrishnan N, Seyfried LS. Describing the relationship between cat bites and human depression using data from an electronic health record. PLoS ONE. 2013;8:e70585.
  34. Webster JP, Kaushik M, Bristow GC, McConkey GA. Toxoplasma gondii infection, from predation to schizophrenia: Can animal behaviour help us understand human behaviour? J Exp Biol. 2013;216:99–112.
  35. Fabiani S, Pinto B, Bruschi F. Toxoplasmosis and neuropsychiatric diseases: Can serological studies establish a clear relationship? Neurol Sci. 2013;34:417–425.
  36. Montoya JG. Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. J Infect Dis. 2002;185:S73-S82.
  37. Meyer U. Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:20–34.
  38. Henriquez SA, Brett R, Alexander J, Pratt J, Roberts CW. Neuropsychiatric disease and Toxoplasma gondii infection. Neuroimmunomodulation. 2009;16:122–133.
  39. Schizophrenia Working Group of the Psychiatric Genomics Consortium: Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014;511:421–427.
  40. Skaper SD, Facci L, Giusti P. Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: A review. CNS Neurol Disord Drug Targets. 2014;13:1654–1666.
© Wroclaw Medical University